- Home
- MREO vs CRBU Comparison
MREO vs CRBU Comparison
Compare MREO & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MREO | CRBU |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | United Kingdom | United States |
| Employees | N/A | 97 |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 50.3M | 48.5M |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MREO | CRBU |
|---|---|---|
| Price | $0.28 | $0.44 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 6 |
| Target Price | $1.97 | ★ $5.75 |
| AVG Volume (30 Days) | 624.0K | ★ 3.8M |
| Earning Date | 11-17-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 16.67 | 3.64 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $500,000.00 | N/A |
| Revenue This Year | N/A | $114.75 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.20 | $0.41 |
| 52 Week High | $2.37 | $2.49 |
Technical Indicators
Market Signals| Indicator | MREO | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 42.10 | 27.27 |
| Support Level | $0.27 | N/A |
| Resistance Level | $0.35 | $0.58 |
| Average True Range (ATR) | 0.02 | 0.04 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 20.85 | 13.25 |
Price Performance
Historical ComparisonAbout MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.